Magellan Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Magellan Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-524	Closed	-$33K	–	81
2017 Q3	$33K	Hold	524	–	–	﹤0.01%	75
2017 Q2	$29K	Buy	524 +70	+15%	+$3.81K	﹤0.01%	75
2017 Q1	$0	Hold	454	–	–	﹤0.01%	69
2016 Q4	$27K	Buy	+454	New	+$24.8K	﹤0.01%	72

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Magellan Asset Management's BMY Position: Q4 2017 in Review

Magellan Asset Management sold out of Bristol-Myers Squibb (BMY) in Q4 2017, closing a stake of 524 shares — an estimated $33K sold.

Magellan Asset Management first reported a position in BMY in Q4 2016 and held it in 4 quarters. The position peaked at $33K in Q3 2017. 1,736 funds tracked by Wall St. Rank hold BMY as of Q4 2017.

Magellan Asset Management reported no remaining Bristol-Myers Squibb position as of Q4 2017 after selling out during the quarter.
Magellan Asset Management sold 524 Bristol-Myers Squibb shares in Q4 2017, an estimated $33K.
Magellan Asset Management first reported a position in Bristol-Myers Squibb in Q4 2016 and held it in 4 quarters.
Magellan Asset Management's Bristol-Myers Squibb position peaked at $33K in Q3 2017.
1,736 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2017.

Based on Magellan Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.